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ADRENERGIC SIGNALING: SYSTEMATIC AND UPDATED OVERVIEW
Adrenergic receptors (also known as adrenoceptors, ARs) belong to the guanine nucleotide-binding G 
protein–coupled receptor (GPCR) superfamily, and are membrane receptors that activate heterotrimeric 
G proteins following the binding of a ligand. GPCRs consist of one extracellular N-terminal domain, 
seven membrane-spanning domains, three intra- and three extracellular loops, and one intracellular 
C-terminal tail (Fig. 11.1). These heptahelical trans-membrane sensors account for approximately 4% 
of the total protein-coding genome and are considered the most important drug targets in medicine 
and physiology. G proteins typically stimulate (via Gs protein) or inhibit (via Gi protein) the enzyme 
adenylyl-cyclase or activate (via Gq protein) phospholipase C (PLC). A detailed and updated overview 
of the main cardiovascular GPCRs was recently published.1 GPCR signaling is terminated by phos-
phorylation of the intracellular domains of the receptor by the family of G protein–coupled receptor 
kinases (GRKs).2,3 GRK-mediated phosphorylation increases the affinity of GPCRs for the arrestin 
class of proteins, which uncouples the phosphorylated receptor from G protein and successively targets 
the receptor for internalization. Downregulation of GPCRs reduces the functional activity of classical 
signaling paradigms up to 80%4,5 (Fig. 11.1).
Two classes of ARs have been identified: αAR and βAR. Phenylephrine is a selective pharmacological 
agonist of αAR while isoproterenol is considered a nonselective agonist for βAR.6 The subfamily of α1AR 
(Gq coupled receptors) consists of three highly homologous subtypes, including α1A-, α1B-, and α1D-AR.7 
The α2AR subfamily (coupled to Gi) comprises three subtypes: α2A-, α2B-, and α2C-AR.8 Some species other 
than humans express a fourth α2D-AR as well.9 In the βAR family there are three receptor subtypes:β1AR 
is found at its highest levels in the heart,10 β2AR is distributed extensively throughout the body,11 and β3AR 
is mainly expressed in the white and brown adipose tissue.12 All three βARs couple primarily to Gαs and 
subsequent cAMP-related pathways, although under certain conditions can also couple to Gαi.13 β2AR and 
β3AR signaling can also occur via G protein independent mechanisms.14 In particular, cardiac β3AR causes 
negative inotropic effects mainly mediated by activation of nitric oxide (NO) synthase, serving thereby as a 
brake in sympathetic overstimulation. These paradigms of signaling can be observed in the same cell type 
based on the functional state of the cell. Henceforth, the response to GPCR stimulus can be modified by 
various conditions, including chronic stimulation, acidosis, cell hypoxia, and aging.15–17
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FIGURE 11.1
G protein–coupled receptor (GPCR) activation and regulation. (A) Binding of a GPCR ligand to the 
extracellular side of the receptor enables the exchange of GDP to GTP by the α subunit of the G protein.  
(B) The GTP-bound α subunit then acts on a second messenger-releasing enzyme such as adenylate cyclase 
(ACA) (Gαs) or phospholipase C (PLC) (Gαq), leading to their activation. (C) Second-messenger molecules 
such as cAMP and inositol-1,4,5-triphosphate (InsP3) are direct products of enzymatic conversion of ATP 
and phosphatidylinositol-4,5-bisphosphate (PIP2) respectively, whereas cytosolic Ca2+ is released upon 
activation of reticular calcium channels. (D) Second-messenger molecules can trigger cascade reactions 
that will lead to a downstream biological event (frequently gene expression regulation). (E) GPCR responsive 
elements such as protein kinases (PKs) or G protein–coupled receptor kinases (GRKs) phosphorylate the 
intracellular side of the receptor and decouple the G protein by steric exclusion. (F) β-Arrestins can recognize 
the phosphorylated GPCR and trigger the internalization process. (G) Modifications on the β-arrestin molecule 
such as dephosphorylation or ubiquitination define the fate of the internalized molecule either to recycling or 
degradation, respectively.
Adapted from Martins SA, Trabuco JR, Monteiro GA, Chu V, Conde JP, Prazeres DM. Towards the miniaturization of GPCR-based live-
cell screening assays. Trends Biotechnol 2012;30(11):566–74. (10.1016/j.tibtech.2012.07.004).
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SYMPATHETIC SYSTEM AND HYPERTENSION
ROLE OF ADRENERGIC SYSTEM IN REGULATION OF VASCULAR HOMEOSTASIS AND 
OXIDATIVE STRESS
The endothelium is central in the regulation of several vascular functions, including vasculature tone 
and permeability, thrombosis, hemostasis, and angiogenesis.18–20 This integrates the overall infor-
mation originating from the bloodstream and furnishing, in a time- and space-dependent manner, a 
fine tuning of vascular homeostasis by releasing specific factors including catecholamines, NO, vaso-
active peptides, arachidonic acid metabolites, and reactive oxygen species (ROS).21 The adrenergic 
system is the major regulator of cardiac and vascular function, and this is accomplished also through 
the activation of specific receptors localized on endothelial surface by local and systemic release of 
catecholamines.22–25
These receptors actively participate in the release of NO to regulate endothelial function.26,27 
Following its release, NO diffuses to the subjacent vascular smooth muscle where it elicits vasore-
laxation through activation of soluble guanylyl-cyclase enzyme, which then catalyzes the formation of 
cGMP and hence activation of cGMP-dependent protein kinase.28,29 Classically, NO is released from 
endothelial cells following activation of the endothelial or type 3 isoform of NO synthase (NOS-3 
or eNOS), which is a Ca2+ and calmodulin-dependent enzyme; hence, many endothelium-dependent 
vasodilators cause NO release via an increase in intracellular Ca2+. However, other pathways have 
also identified to act in Ca2+ independent manner and involve phosphorylation of various eNOS serine 
residues by a number of protein kinases.30 Such a mechanism is particularly evident for β2AR signaling 
where activation of eNOS involves specific kinases such as protein kinase A (PKA) and AKT.31 The 
impaired ability of endothelium to appropriately vasodilate is defined as “endothelial dysfunction” and 
the major cause is decreased NO bioavailability (Fig. 11.2). Endothelial dysfunction has been associ-
ated with development of several cardiovascular disorders including hypertension, type 2 diabetes mel-
litus, and heart failure.21,32
However, altered NO production is not the only feature of the endothelial dysfunction. Indeed, 
increased ROS bioavailability and dysregulated redox signaling (oxidative stress) together with 
decreased NO production and increased NO consumption by ROS contribute to many of the molecular 
events underlying endothelial injury. 33,34 These findings have modified the molecular definition of 
endothelial dysfunction, leading to the concept of “eNOS uncoupling,” characterized by the discrep-
ancy between eNOS protein levels and NO production, with a switch in the enzymatic activity of eNOS 
to generate superoxide (O2) rather than NO.
35
ADRENERGIC SIGNALING AND ROS
ROS are products of normal cellular metabolism and derived from many sources in different cellular 
compartments. Enzymatic sources of ROS in endothelial cells include uncoupled NOS, xanthine oxi-
doreductase, mitochondrial respiratory enzymes, and NADPH oxidase.36–38 However, the perceived 
role of ROS in regulation of cellular physiology has changed in the recent years. Indeed, on the one 
hand they can be considered detrimental for cell survival; however, they also have important physi-
ological roles and act as part of the intracellular signaling, promoting beneficial cellular process such 
as mitohormesis (e.g., replacement and organization of the mitochondrial network), induction of host 
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defense genes, activation of transcription factors and stimulation of ion transport systems.39 In the 
vascular system, ROS play a physiological role in controlling endothelial function, vascular tone, and 
vascular integrity but also a pathophysiological role in inflammation, hypertrophy, proliferation, apop-
tosis, constriction, migration, fibrosis, angiogenesis, and rarefaction, important factors contributing 
to endothelial dysfunction, vascular contraction, and arterial remodeling in cardiovascular diseases. 
FIGURE 11.2
Mechanisms underlying endothelial (vascular) dysfunction in vascular disease. An unbalanced  
production of nitric oxide (NO) and superoxide (O2−) leads to inappropriate formation of peroxynitrite 
(ONOO−). Peroxynitrite and superoxide cause vascular dysfunction through several mechanisms (reviewed 
in Forstermann and Munzel [1]). Peroxynitrite is a strong inhibitor of NO and prostacyclin (PGI2) signaling, 
and it may cause eNOS uncoupling, causing this enzyme to produce superoxide instead of NO. ADMA = 
asymmetrical dimethylarginine; cGMP = guanosine 3 ′ ,5 ′ -cyclic monophosphate; cGK = cGMP-dependent 
kinase; eNOS = endothelial nitric oxide synthase; ET = endothelin; sGC = soluble guanylate cyclase; TXA = 
thromboxane.
From Münzel T, Gori T. Nebivolol. J Am Coll Cardiol 2009;54(16):1491–9. (10.1016/j.jacc.2009.05.066).
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These various lines of evidence suggest ROS as a specific cellular messenger able to promote either 
cellular survival and adaptation or apoptosis, according to the specific characteristics of the stressors. 
According to this view, the physiological or pathological ROS level is more likely to be associated 
to the impaired redox signaling and equilibrium rather than the imbalance between pro-oxidants and 
antioxidants.40
The adrenergic system is also implicated in ROS production by the endothelium. Mounting evi-
dence suggest an important roles for catecholamines in vascular cell growth and tissue remodeling 
following atherosclerosis, hypertension, and vascular injury.41 Meanwhile, noradrenaline (norepineph-
rine) is also known to be a potential pro-inflammatory factor, since noradrenaline induces TNF-α, 
matrix metalloproteinase (MMP)-2, MMP-9, ROS, and toll-like receptor (TLR4) release from cells.42  
Furthermore, data suggest that noradrenaline stimulates the phosphorylation of mitogen-activated pro-
tein kinases (MAPK) and ROS synthesis leading to cell proliferation in vitro.43
THE ROLE OF G PROTEIN–COUPLED RECEPTOR KINASE 2 IN VASCULAR 
HOMEOSTASIS
GRKs have a significant role in adrenergic regulation of endothelial function (Figs. 11.1 and 11.2). 
Of the seven mammalian isoforms of GRKs, G protein-coupled receptor kinase 2 (GRK2) appears to 
be the most important isoform related to cardiac physiology. GRK2 is found in the striated (heart and 
skeletal) and smooth muscle in addition to WBCs (bone marrow, lymph nodes, and thymus) and many 
other organs. Indeed, homozygous GRK2-deficient mice exhibited embryonic lethality whereas gene 
ablation for the other GRKs resulted in relatively mild phenotypes.44–46 The physiological relevance 
of GRK2 was further confirmed by its participation in diverse fundamental cellular processes, includ-
ing cell cycle progression, migration, and differentiation.47,48 Notably, GRK-mediated desensitization 
does not always rely on its catalytic activity but also on protein–protein interactions49,50 that occur in 
different cellular compartments.51 It is likely that both up- and downregulation of GRK2 affect cellular 
function and survival. Alterations in GRK2 expression and activity were observed in several diseases, 
such as heart failure,2 Alzheimer’s disease,52 multiple sclerosis,53 thyroid gland disorders,54 opioid 
addiction,55 rheumatoid arthritis,56 ovarian cancer,57 and cystic fibrosis.58
GRK2 participates in the development of experimental portal hypertension, which appears depend-
ent upon the physical interaction between GRK2 and AKT.59 Since AKT is able to activate eNOS, 
the GRK2-mediated inhibition of AKT shifts the vascular tone toward constriction in the setting of 
endothelial dysfunction due to decreased eNOS activity.59 Given its close relationship to the adren-
ergic system, GRK2 may represent the specific link between adrenergic system and endothelial ROS 
production.
The functional role of GRK2 in vascular smooth muscle cells was explored in a transgenic animal 
model (targeted overexpression of GRK2),60 where mice exhibited an increase in resting mean arte-
rial pressure accompanied by an attenuated response to β-AR signaling compared with nontransgenic 
littermates. The increased blood pressure was also accompanied by cardiac hypertrophy and vascular 
thickening, two hallmarks of hypertensive phenotype.60
The endothelium-mediated modulation of the contractile state of vascular smooth muscle is impaired 
in atherosclerosis and in several conditions associated with the premature development of atheroscle-
rosis.61 The correlation between GRK2 abundance and hypertension is also present in other condi-
tions characterized by increased blood pressure, such as portal hypertension59 and preeclampsia.62 In 
gestational hypertension, the increase in GRK2 in the placental vasculature seems to be compensatory 
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rather than causative of increased blood pressure. This compensation helps balance the excessive vas-
cular tension as the lack of protective effect of elevated GRK2 expression levels negatively affect the 
outcome of the hypertensive state.62 In this case, a potential explanation could rely on the metabolic 
effect of GRK2, which is able to place the cell in a low energy state that might favor survival in stress 
conditions.51,63–65
GRK2 levels in peripheral blood lymphocytes was reported to mirror changes in kinase expression 
in other organs under several pathophysiological settings. In particular, GRK2 levels and activity were 
increased in lymphocytes from hypertensive patients. Impairment of β-adrenergic-mediated vasodila-
tion was reported in both human hypertensive subjects22,66 and animal models of hypertension67; such 
alterations have been related to the increased GRK2 abundance and activity.66 Decreased β-adrenergic 
signaling due to increased GRK2 activity would reduce the vasodilatative response, leading to high 
blood pressure. This view is supported by the inverse correlation of GRK2 expression with blood 
pressure.68 Other data from spontaneously hypertensive rats and Dahl salt-sensitive rats confirmed 
increased levels of GRK2 in vascular smooth muscle cells, consistent with the observations in periph-
eral lymphocytes.69 An subsequent study observed higher GRK2 protein levels in circulating lympho-
cytes from patients with myocardial infarction; additionally, increased GRK2 levels associated with 
worse systolic and diastolic function.70 Importantly, at 2-year follow-up patients with higher GRK2 
levels at admission had worse systolic function and cardiac remodeling,70 suggesting that GRK2 levels 
may reflect hemodynamic impairment and might have a meaningful prognostic value after myocardial 
infarction (Fig. 11.3).
Elevated GRK2 levels might imply metabolic alterations and lead to insulin resistance, a common 
feature of hypertensive state.14,71,72 In myoblasts, increased GRK2 expression mediated insulin resist-
ance via a mechanism that involves sequestration of Gq and the insulin receptor substrate-1 (IRS-1).
73 
In addition, GRK2 was shown to bind and phosphorylate IRS1 and the inhibition of GRK2 action 
ameliorated insulin sensitivity.74,75 Also, GRK2 negatively affected cardiac glucose uptake and lower-
ing GRK2 after ischemic injury contributed to restoring cardiac metabolism and prevented the devel-
opment of subsequent heart failure.72,74 GRK2 appears to regulate cardiomyocyte function in part by 
controlling β1-AR in the regulation of cardiac contractility and chronotropy; interestingly, GRK3 was 
implicated in the regulation of cardiac growth and hypertrophy by selectively controlling endothelin 
and α1-AR (PMID 17573483). Taken together, the control of endothelial homeostasis relies on a com-
plex interaction between adrenergic system and nitroxidative stress; specific molecules such as GRKs 
may interplay with and modulate the crosstalk across multiple cell types involved in vascular function.
ADRENERGIC SIGNALING IN HEART FAILURE
The sympathetic nervous system (SNS) has pronounced effects on cardiac physiology, including 
increases in atrioventricular conduction (positive dromotropy), heart rate (positive chronotropy), car-
diac contractility (positive inotropy), and cardiac relaxation (positive lusitropy). Likewise, the SNS 
plays a crucial role in the regulation of vascular tone due by controlling peripheral resistance and 
cardiac output.76
Heart failure is a chronic clinical syndrome in which the heart is incapable of pumping a sufficient 
supply of blood to meet the metabolic requirements of the body or generating the required elevated ven-
tricular filling pressures to maintain output.72 Heart failure leads to a debilitating illness characterized by 
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poor exercise tolerance and chronic fatigue, representing one of the most important causes of morbid-
ity and mortality worldwide. Notwithstanding considerable advances in its treatment, heart failure still 
represents a severe social and clinical burden.77,78 A complex neurohormonal regulatory system exists 
between the heart and multiple organ systems, including feedback loops mediated through a variety of 
vasoactive substances secreted by the adrenals, kidneys, lungs, and endothelium.79 Perturbations of func-
tion in any of these organs affect the others. Accordingly, the cardiovascular system is best viewed as a 
FIGURE 11.3
GRK2 levels and outcomes after myocardial infarction. (A) Two years after myocardial infarction, patients 
with higher GRK2 levels at admission had worse systolic function, with lower stroke volumes, than those with 
low GRK2 levels (independent-samples Student’s t-test). (B) Also, cardiac remodeling, assessed by  
the change in end-systolic volume (ESV) corrected by body surface area (BSA) after 2 years of follow-up  
(Δ%-ESV/BSA) was correlated with GRK2 level at admission (r2 = 0.25, p < 0.05).
From Santulli G, Campanile A, Spinelli L, et al. G protein-coupled receptor kinase 2 in patients 
with acute myocardial infarction. Am J Cardiol 2011;107(8):1125–30.
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complex dynamic system, continually adapting to optimize organ perfusion. During heart failure, diverse 
neurohormonal mechanisms are triggered to maintain cardiac output.4 Heart failure is indeed a progres-
sive disease that begins long before symptoms or signs become evident. It is initially characterized by a 
complex adaptive neurohormonal activation, which includes the nervous system (see chapter: Neuronal 
Hormones and the Sympathetic/Parasympathetic Regulation of the Heart), the renin-angiotensin-aldoster-
one system (see chapter: Renin Angiotensin Aldosterone System and Heart Function), natriuretic peptides 
(see chapter: Cardiac Natriuretic Peptides), endothelin (see chapter: Endothelin-1 as a Cardiac-Derived 
Autocrine, Paracrine and Intracrine Factor in Heart Health and Disease), and vasopressin (see chapter: 
Renin Angiotensin Aldosterone System and Heart Function). These and other regulatory mechanisms are 
required to compensate for cardiac dysfunction80; however, the process progressively becomes maladap-
tive when the left ventricular (LV) dysfunction is persistent. This eventually leads to increased mechani-
cal stress on the failing heart, causing detrimental electrical and structural events, further impairment of 
systolic and diastolic function, and progressive cardiac fibrosis and apoptosis.81 Thus, β-blockers, angio-
tensin-converting enzyme inhibitors, Angiotensin II AT1 receptor blockers and mineralocorticoid receptor 
antagonists represent cornerstones for the treatment of patients with a failing heart.82
The central part of the adrenal gland, called adrenal medulla, is the main source of catecholamines 
and comprises groups of adrenergic and noradrenergic chromaffin cells and, to a lesser extent, gangli-
onic neurons.83 Chromaffin cells secrete roughly 80% adrenaline and 20% noradrenaline whereas this 
proportion is reversed in the sympathetic nerves, which contain and secrete predominantly noradrena-
line.79 The adrenergic and noradrenergic secretion in different groups of chromaffin cells relies on the 
different α2AR subtypes expression.84 The adrenal gland can be compared to a specialized sympathetic 
ganglion, receiving inputs from the SNS via preganglionic fibers.85 However, the adrenal gland directly 
secretes neurohormones into the bloodstream. Indeed, chromaffin cells are postganglionic sympathetic 
neurons that have lost part of their characteristics as axons and dendrites and are able to secrete their 
hormones into the blood by exocytosis. The suggestive link between the adrenal gland and the heart 
has become quite interesting and stimulating in the last few years, with several studies investigating 
the molecular mechanisms underlying such a complex relationship, especially in the pathophysiology 
of heart failure.79
Adrenaline and noradrenaline generally have similar effects, although they differ from each other in 
certain of their actions. In particular, noradrenaline constricts almost all blood vessels, while adrenaline 
constricts many networks of minute blood vessels but dilates the vessels in the skeletal muscles and 
the liver.86 Both sympathomimetic agents increase heart rate and myocardial contractility, thereby aug-
menting cardiac output and blood pressure.87 Sympathetic overdrive observed in heart failure correlates 
with a higher risk of arrhythmias and LV dysfunction.88 Plasma concentrations of noradrenaline are 
negatively associated with survival in heart failure patients.89 Augmented levels of circulating catecho-
lamines can cause myocardial damage via enhanced cardiac oxygen demand and by increasing peroxi-
dative (and lipoperoxidative) metabolism and the ensuing production of free radicals.90 These reactive 
species lead to structural alterations in the myocardium, including focal necrosis and inflammation, 
increased collagen deposition and subsequent interstitial fibrosis.91 Noradrenaline can also increase 
cardiac oxygen consumption and cause apoptosis, ultimately leading to dilated cardiomyopathy.92,93
At the vascular level, systemically circulating or locally released catecholamines94 trigger two main 
classes of ARs: α1AR and β2AR, causing vasoconstriction and vasodilatation, respectively.23,95 With 
aging, such a fine equilibrium is progressively shifted toward increased vasoconstriction, most likely 
due to a defective vasodilatation in response to βAR stimulation. Supporting this hypothesis, βAR 
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agonist administration in the human brachial artery induces vasodilatation and this response is attenu-
ated in hypertensive patients.66 The mechanistic role of β2AR in the vasculature is also corroborated by 
the fact that genetic variants of β2AR cause excessive desensitization and lead to reduced vasodilation, 
promoting the development of atherosclerosis.96
Increased basal levels of circulating catecholamines were observed both in heart failure and with 
advancing age, mirrored by a decrease in the number of high-affinity βARs, suggesting that these alter-
ations might be due to βAR desensitization rather than actual reduction in βAR density.11 As mentioned 
above, βAR affinity for the ligand is mainly dependent upon GPCR phosphorylation, which in turn is in 
the domain of GRKs.70 Modulation of sympathetic nervous signaling via GRKs mediated downregula-
tion of βARs in the heart plays a key role in heart failure. In particular, heterozygous GRK2 knockout 
mice display augmented cardiac contractility and function, whereas transgenic mice overexpressing 
cardiac GRK2 exhibit decreased myocardial function due to βAR dysfunction.97
GRK2 expression and activity increase in vascular tissue with aging.1 Equally important, an impair-
ment in βAR-mediated vasorelaxation was observed in hypertensive patients66 and in animal models 
of hypertension21,67: these alterations related to increased GRK2 abundance and activity. Transgenic 
overexpression of GRK2 in the vasculature impaired βAR signaling and the vasodilatative response, 
eliciting a hypertensive phenotype in rodents. This aspect was confirmed in humans: GRK2 expression 
correlated with blood pressure and impaired βAR-mediated adenylyl-cyclase activity.1 Additionally, 
genetic variants of the β2AR that affect its translational efficiency associated with longevity.11 The 
decrease in βAR-mediated responses were attributed to different mechanisms, including attenuation of 
PKA activation, impaired generation of cyclic AMP, decreased receptor density, and less efficient cou-
pling to adenylyl-cyclase.11 Variations in cyclooxygenase expression and vasoactive prostanoids levels 
are suggested as potential mechanisms. However, currently there is no single molecular or cellular fac-
tor that fully explains the decline in βAR function. Nevertheless, the etiology seems to be most likely 
associated with alterations in the ability of βAR to respond to agonists at the cellular level.
ADRENERGIC SYSTEM IN THE HEART: BEYOND THE REGULATION OF 
CONTRACTILITY
The activation of the sympathetic system leads to noteworthy metabolic responses, including increased 
gluconeogenesis and lipolysis with subsequent elevated plasma levels of free fatty acids (FFAs) and 
glucose.98,99 Essentially, the increased availability of glucose and FFAs can be used by the organism as 
fuel in times of stress or danger, when increased exertion or alertness is required.100 Different therapeu-
tic approaches targeting myocardial metabolism have been suggested to regulate metabolic pathways in 
the failing heart, in an attempt to improve cardiac function and metabolic elasticity.101
During the flight or fight response, sympathetic activation causes α1-AR–mediated vasoconstriction 
in less vital vascular beds, including splanchnic and skin, diverting blood to skeletal muscle. AR activa-
tion also mobilizes blood from the capacitance veins, involving α1 and α2ARs.102 These acute physi-
ological responses, typical of the stress conditions, are disadvantageous when they become chronic. 
Actually, a common feature of many pathological conditions involving sympathetic system hyperac-
tivity is the development of metabolic alterations, including insulin resistance, impaired glucose and 
lipid metabolism, and mitochondrial dysfunction.103,104 The myocardium has high metabolic demands, 
among the highest in the body: with minimal ATP reserves and complete ATP turnover approximately 
every ten seconds, the heart heavily depends on a continuous energy supply,105 though the heart 
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possesses a strategic metabolic flexibility that supports its function during stressful conditions. Cardiac 
muscle generates ATP almost exclusively via oxidative phosphorylation by using different metabolic 
substrates: in the healthy state cardiac ATP production mainly relies on FFA oxidation, whereas the 
relative contribution of glucose increases during stress or injury.106
Imbalance in adrenergic activation and cardiac energy metabolism represents a risk factor for the 
development of cardiac disease. Therefore, heart failure represents a classical endpoint in the study 
of metabolic alterations related to the sympathetic system. Indeed, there are multiple disturbances 
in various metabolic pathways, including the tricarboxylic acid cycle and β-oxidation in heart under 
pathological conditions. Metabolic remodeling observed in failing hearts is characterized by a lower 
oxidative capacity, contractile dysfunction, and insulin resistance.107,108 Circulating insulin levels are 
chronically augmented in both type 2 diabetes mellitus and heart failure, leading to persistent stimula-
tion of insulin receptors109,110 (see chapter: Insulin Signaling in Cardiac Health and Disease). Such an 
increase in insulin signaling in the heart promotes FFAs uptake and enhances lipotoxicity.111 Moreover, 
hyperactive insulin signaling also accelerates adverse LV remodeling.112,113 Insulin itself can directly 
impair adrenergic signaling pathways required for contractile function via an insulin receptor/β2AR 
signaling complex,107 providing a potential novel mechanism underlying cardiac dysfunction in heart 
failure. Of note, insulin resistance highly correlates with neuroadrenergic function,21 and the onset of 
type 2 diabetes is associated with increased central sympathetic outflow.114 In addition, both nutritional 
sympathetic responsiveness and baseline sympathetic drive are important prognostic biological mark-
ers for dietary weight loss outcome in obese subjects with metabolic syndrome.115,116
The prevalence of sympathetic over parasympathetic activity might be initially responsible, at least 
in part, for an increased metabolic state. However, as in different hormone-regulated pathways, such 
a state is subsequently followed by a decrease in βAR metabolic responsiveness. This compensatory 
response results in a reduced basal metabolic rate and an increased tendency toward anabolic processes, 
leading to insulin resistance and reduced ability to dissipate energy, with an overall weight gain, par-
ticularly at the visceral level.117 This complex metabolic network can eventually cause a vicious circle, 
where insulin resistance further stimulates sympathetic activity, worsening insulin resistance itself. A 
sustained βAR stimulation is widely known to induce insulin resistance.118 β2ARs and β3ARs seem to 
play a pivotal, although not exclusive, role in regulating glucose and lipid homeostasis, respectively: 
whereas β2AR regulates both pancreatic β-cell hormone secretion and peripheral glucose metabo-
lism,14 β3AR is more involved in the modulation of FFAs metabolism.119 GRKs actively participate in 
this complex scenario. In fact, GRKs have been proposed as pleiotropic proteins involved in the regula-
tion of countless cellular functions, not exclusively via the classic phosphorylation pathway. Mounting 
evidence indicates that GRKs exert different effects depending on cell type, localization, stimuli, and 
pathophysiological context.120–123 For instance, Iaccarino and colleagues were the first to demonstrate 
the mitochondrial localization of GRK2,51 later confirmed by other investigators124 with imperative 
functional implications (Fig. 11.4).
Insulin also up-regulates GRK2, which in turn inhibits insulin signaling and glucose uptake.1,125 
Various conditions associated with insulin resistance, including hypertension and diabetes, are char-
acterized by elevated GRK2 levels.1 In murine failing hearts, GRK2 inhibition was demonstrated to 
be beneficial, preventing the derangement of insulin signaling and delaying the reduction of glucose 
uptake, thereby preserving myocardial function.74 In the clinical setting, lymphocyte GRK2 levels were 
augmented in patients with end-stage heart failure126 and in patients with myocardial infarction, cor-
relating with a worse systolic and diastolic function.70
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ADRENERGIC RECEPTORS AND CARDIAC METABOLISM
Cardiac function relies to a great extent on oxidative metabolism. Given its the high mitochondrial 
content cardiac muscle generates ATP almost exclusively through oxidative phosphorylation.127 
Accordingly, cardiac muscle possesses a metabolic flexibility or plasticity, allowing it to maintain 
its function during stressful conditions. In the adult heart the major pathway for ATP production is 
fatty acid oxidation, while the relative contribution of glucose increases during stress or injury, such 
as exercise or ischemia.128,129 Thus, it is not surprising that an impairment of cardiac muscle energy 
metabolism represents an important risk factor for the development of cardiac diseases.130 The heart 
exhibits a severe malfunction of different pathways with a metabolic remodeling characterized by a 
lower oxidative capacity, contractile dysfunction, and cardiac muscle insulin resistance under patho-
logical conditions.127,130 Different therapeutic strategies have been undertaken to modulate metabolic 
FIGURE 11.4
Intracellular localization of GRK2. GRK2 is localized to the cytosol in resting conditions, but GRK2 
translocates in response to a variety of stimuli to different subcellular compartments where GRK2 regulates 
several cellular functions, including GPCR and IR desensitization at the plasma membrane level, actin 
polymerization in the cytoskeleton, metabolism, and ROS production in mitochondria. GPCR: G protein–
coupled receptor; IR: insulin receptor.
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pathways in the failing heart, though it remains controversial whether targeting glucose versus fatty 
acid metabolism individually or in combination represents an optimal approach to improve metabolic 
flexibility and cardiac function.131
Activation of the adrenergic system is deeply involved in regulating diverse metabolic pathways. 
Increased circulating catecholamines and activation of the different adrenergic receptors present in 
the various organs produce important metabolic responses which include: (1) increased lipolysis and 
elevated levels of fatty acids in plasma, (2) increased gluconeogenesis by the liver to provide substrate 
for the brain, and (3) moderate inhibition of insulin release by the pancreas to conserve glucose and to 
shift fuel metabolism of muscle in the direction of fatty acid oxidation (Fig. 11.5). This physiological 
FIGURE 11.5
The metabolic vicious circle in heart failure. Dilation of the myocardium in heart failure (A) leads to 
adrenergic activation (B) that in turn hyperphosphorylates the SR (C) and increases concentrations of 
circulating FFA (D). FFA inhibit mitochondrial function at the level of ACT (E), thus inhibiting fatty acid 
oxidation and synthesis of ATP (F). Plasma FFA also inhibit PDh (G) to promote anaerobic glycolysis (h) rather 
than oxidative metabolism. SR = sarcoplasmic reticulum. RyR = ryanodine receptor. FFA = free fatty acids. ACT 
= acyl carnitine transferase. PDH = pyruvate dehydrogenase. GLUT-4 = glucose uptake transporter 4.
Adapted from Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L. Cardiovascular remodelling in coronary artery 
disease and heart failure. Lancet 2014;383(9932):1933–43. (10.1016/S0140-6736(14)60107-0).
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response, typical of the stress condition, was demonstrated to be detrimental for the functioning of 
different organs like the cardiac muscle when it becomes chronic. Indeed, a common feature of many 
pathological conditions involving over-activation of the adrenergic system is the development of meta-
bolic alterations which can include insulin resistance, altered glucose and lipid metabolism, and mito-
chondrial dysfunction.104 These alterations are seen in a number of different pathological conditions; 
however, they are, in general, highly correlated to the level of activation of the adrenergic system.
The SNS is maladaptively activated in response to a chronic reduction in cardiac output and this 
response is characterized by an increased adrenal secretion and reduced cardiac reuptake of catecho-
lamines.132 The effects of the catecholamine secretion on cardiac metabolism are mediated by both 
central and peripheral mechanisms. For example, increased catecholamines have directly detrimental 
effects on the heart, which cause marked enzyme loss as an index of diffuse myocardial damage, and 
substantial oxygen-wastage even in the absence of FFAs in the perfusate.133,134 Furthermore, noradren-
aline promotes both coronary vasoconstriction and increased plasma FFA levels, which further promote 
oxygen-wastage.134 In turn, FFAs reciprocally augment sympathetic activity. In human skeletal muscle, 
a dose-response relationship exists between plasma FFAs135 and defects in insulin signaling. This may 
in part be attributable to FFA-mediated activation of PKC, which phosphorylates insulin receptors and 
results in reduced capillary opening and reduced myocyte glucose uptake.136
Locally activated SNS appears to be relevant in altering cardiac metabolism. Using positron emis-
sion tomography in conjunction with a noradrenaline analog and 18F-fluorodeoxyglucose, myocardial 
segments with contractile dysfunction have reduced presynaptic noradrenaline reuptake and myocar-
dial glucose uptake, compared to less impaired myocardial segments in the same patients.118 Thus, 
after control for confounding variables, altered metabolism and insulin resistance directly relate to 
local sympathetic activity. The adverse effects of the SNS on the heart are mediated by ARs; however, 
extensive research indicates that ARs are differently involved in pathophysiology of heart failure, and 
so it is likely to be the same for modifications of cardiac metabolism observed during disease. Indeed, 
β1- and β2-adrenoceptors regulate different signal pathways, producing different outcomes on cardiac 
function. Stimulation of both β1AR and β2AR can activate the stimulatory G protein (Gαs)/adenylyl-
cyclase/cAMP/PKA signaling pathway, which subsequently leads to the phosphorylation of several 
target proteins within the cardiac myocyte, including intracellular calcium release channels (ryanodine 
receptors), L-type calcium channels, and phospholamban16,127,137 (Fig. 11.1). Nonetheless, this signal-
ing pathway is the main mechanism by which β1AR rather than β2AR regulates cardiac contractility/
relaxation and rate.138 In contrast, β2ARregulates an alternative signaling pathway via activation of the 
inhibitory G protein (Gαi) and the heterodimer formed by the β and γ subunits of the G protein (Gβγ).13 
Besides the inhibition of adenylyl-cyclase, the main signal pathway regulated by β2AR through Gαi/
Gβγ appears to be the phosphatidylinositol-3 kinase (PI3K)–signaling cascade, although other proteins 
such as the AMP-dependent protein kinase (AMPK), mammalian target of rapamycin, and extracellular 
signal-regulated kinase 1 and 2 (ERK1/2) have been proposed as novel targets of β2AR.139,140
Regarding the effects of adrenergic system on metabolism, it is known that sustained beta adren-
ergic stimulation induces insulin resistance and in this context the β2AR appears to have a major role 
in overall glucose homeostasis by modulating pancreatic islet hormone secretion as well as liver and 
muscle glucose homeostasis. For the heart, several studies have raised the possibility of using selective 
β2AR agonists as potential modulators of cardiac muscle energy metabolism. Short- and long-term 
stimulation of the β2AR has been associated with the modulation of fatty acid and glucose metabo-
lism.141 Indeed, acute treatment of myocytes in vitro or skeletal muscle ex vivo with β2AR agonists 
increases glucose uptake to levels comparable to those seen after insulin stimulation.142
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A putative mechanism for β2AR function in insulin resistance involves the activation of PI3K and 
its downstream signal pathway143,144 and in particular the phosphorylation and inactivation of TBC1D4 
(also known as AKT substrate of 160 kDa, AS160) by AKT.145 TBC1D4 inhibits the translocation of 
the glucose transporter type4 (GLUT4) from intracellular vesicles to the plasma membrane, hence 
an increase in TBC1D4 phosphorylation enhances glucose uptake.145 Moreover, TBC1D4 is also tar-
geted by AMPK, which represents a key mechanism in the regulation of insulin-independent glucose 
uptake.145,146 Consistent with the potential role of β2AR in glucose metabolism, higher levels of AMPK 
phosphorylation, and activity was seen in response to βAR stimulation109,147 as a result of changes in 
the AMP/ATP ratio or activation of upstream AMPK kinases.148 Therefore, it is tempting to speculate 
that β2AR-agonists would induce GLUT4 translocation in this situation in an insulin-independent man-
ner. Moreover in vivo studies show a greater efficiency of carvedilol, a nonselective beta AR antagonist, 
in ameliorating myocardial insulin sensitivity and glucose extraction in an animal model of heart fail-
ure, compared to the selective β1AR antagonist metoprolol.149 These conflicting results may be due to 
differences in preclinical models but are more likely due to differences in response to acute and chronic 
stimulation of the β2AR. While acute activation of the receptor can favor glucose uptake by increasing 
GLUT4 translocation to the plasma membrane, chronic adrenergic stimulation, as seen during heart 
failure, would be detrimental by mechanisms involving other molecular mechanisms, such as JNK, 
β-arrestins, and GRKs.4,150
ROLE OF ADRENERGIC RECEPTORS IN THE PATHOPHYSIOLOGY OF CARDIAC 
HYPERTROPHY
Cardiac hypertrophy can be observed in both physiological and pathological conditions where the 
increased hemodynamic or metabolic stress produces a remodeling of cardiac geometry.151,152 However, 
under pathological conditions the hypertrophy is not compensatory, rather it reflects activation of mala-
daptive cellular processes that promote disease progression. In this sense, myocardial hypertrophy might 
serve as diagnostic and prognostic marker of cardiac remodeling (Fig. 11.6), and underlies several bio-
chemical and molecular changes involved in metabolic and contractile regulatory pathways.153,154
The pathways attributed to pathological hypertrophy promoted the identification of specific pharma-
cological targets able to counteract adverse remodeling and foster prognosis improvement. Common trig-
gers of cardiac remodeling include hypertension, myocardial infarction, chronic ischemia, inflammation, 
valvular disease, prolonged tachycardia or bradycardia, and genetic predisposition.113 Cardiac remod-
eling represents the result of increased cell death (apoptosis and/or necrosis) and hypertrophy of the sur-
viving cardiomyocytes. A resulting increase in LV mass is defined by LV wall thickness and LV diameter 
as concentric or eccentric hypertrophy.155 In LV concentric hypertrophy cardiomyocytes grow thicker but 
retain normal length, while dilation of the LV in eccentric hypertrophy is associated with cardiomyocyte 
elongation through sequential addition of sarcomeres.156 The type of hypertrophic remodeling depends 
on the trigger and concomitant progression of contractile dysfunction, such that concentric hypertro-
phy is a common response to increased afterload (valve stenosis, hypertensive heart disease), whereas 
eccentric hypertrophy is often observed in conditions of LV volume overload (e.g., valve regurgitation 
or shunt) or after myocardial infarction (as a late response).157 Overall, cardiac hypertrophy can be con-
sidered a general term that indicates both concentric hypertrophy, with prevalent diastolic dysfunction, 
and eccentric hypertrophy with prevalent systolic dysfunction. These two patterns of cardiac remodeling 
represent the two extremes of a continuum.158 Clinical echocardiography defines four distinct geometric 
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FIGURE 11.6
Myocardial remodeling in response to pressure load. Proposed transition from pressure load to concentric 
hypertrophy to dilated failing left ventricle (lV). Concentric remodeled myocardium undergoes splitting of the 
collagen crosslinks in response to modifying molecular signals such as metalloproteinases and other signals 
that disrupt collagen crosslinks to promote lV dilation and systolic heart failure. LVF = left ventricular failure. 
LVH = left ventricular hypertrophy.
Adapted from Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L. Cardiovascular remodelling in coronary artery 
disease and heart failure. Lancet 2014;383(9932):1933–43. (10.1016/S0140-6736(14)60107-0).
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patterns: (1) normal geometry, (2) concentric remodeling, (3) concentric hypertrophy, and (4) eccentric 
hypertrophy.159 Additionally, nine intermediate phenotypes have been recently identified.160
Activation of the SNS in response to normal or disease-related stimuli is essential to maintain 
homeostasis and for the body to adapt in a constantly changing environment. The physiological and 
metabolic responses to sympathetic activation are mediated through the action of the endogenous cat-
echolamines on adrenergic receptors. Regulation of cardiac function in response to catecholamine 
stimulation is controlled primarily through activation of βARs. As mentioned above, both β1 and β2AR 
subtypes couple to Gs and activate adenylyl-cyclase, thereby increasing cAMP levels and activating 
PKA.161 In addition to Gs, β2ARs also possess a nonclassic pathway through which are coupled to Gi 
(pertussis-toxin sensitive pathway).162 Studies in neonatal cardiomyocytes of β2AR knockout mice 
showed that stimulation of β2AR is characterized by a biphasic effect on contraction rate with an ini-
tial PKA-independent increase in rate, followed by a PTX-sensitive decrease in rate of contraction.163 
Switching of β2AR from Gs to Gi-coupling was found not only to inhibit adenylyl-cyclase activity but 
also to initiate signaling of MAPK by the Gβγ subunits of Gi in a process that is regulated by PKA-
mediated phosphorylation of the receptor. βAR/Gi coupling can also activate the cytosolic effector 
molecule phospholipase A2 (cPLA2) in the heart in a cascade that triggers positive enhancement of 
calcium signaling and contraction, and which is independent of cAMP production.164 In contrast with 
β1-β2ARs, β3ARs are expressed at very low levels in the unstressed heart and are upregulated in various 
conditions with adrenergic overstimulation. Moreover, β3ARs are typically activated by high concen-
trations of catecholamines (e.g., noradrenaline), are resistant to homologous desensitization, and their 
activation has potential negative inotropic effects since genetic deletion of β3ARs results in enhance-
ment of cardiac myocyte contractility.165
Transgenic overexpression of β3ARs in the mouse heart was described as a neutral phenotype, with 
no deterioration of LV function at baseline.166 However, systemic deletion of β3ARs in mice subjected 
to transverse aortic constriction produced an adverse cardiac phenotype, thus arguing in favor of pro-
tection conferred by β3ARs.167 Nonetheless, mouse models with cardiac-specific overexpression of the 
human β3ARs subjected to various neurohormonal stresses appear protected from hypertrophic and 
fibrotic remodeling. Dissection of signaling in isolated cardiomyocytes identifies β3AR coupling to 
NOS/cGMP and downstream protein kinase G (PKG) as key components for this protection.12
Cardiac hypertrophy and heart failure are typically characterized by derangement of βARs sign-
aling and a reduction of the adrenergic reserve of the heart.168 This is primarily due to the selective 
reduction (downregulation) of β1AR density at the plasma membrane and by the uncoupling of the 
remaining β1ARs and β2ARs from G proteins (functional desensitization). Moreover β2AR signaling 
in the failing heart is different from that seen in the normal heart, switching from a compartmentalized 
to a diffuse pro-apoptotic cAMP signaling pattern, similar to that seen for the β1AR.169 These modifi-
cations are strictly connected to myocardial levels and activities of the most important, versatile, and 
ubiquitous GRKs, GRK2, and GRK5, which were elevated both in humans and in animal models of 
heart failure.2 Excessive catecholamines stimulation of cardiac βARs triggered the GRK2 upregulation 
in cardiomyocytes, thus leading to a reduction in cardiac βAR density and responsiveness, ultimately 
resulting in cardiac inotropic reserve depletion.4,170 Such GRK2 elevation is a homeostatic protec-
tive mechanism aimed at defending the heart against excessive catecholaminergic toxicity.151 Thus, 
elevated sympathetic activity in chronic heart failure cause enhanced GRK2-mediated cardiac β1AR 
and β2AR desensitization and β1ARs downregulation, eventually leading to the progressive loss of the 
adrenergic and inotropic reserves of the heart.
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GRK2 SUBCELLULAR LOCALIZATION: A MOLECULAR LINK BETWEEN MYOCARDIAL 
CONTRACTILITY AND CARDIAC METABOLISM
Activation of the adrenergic system has a profound effect on cell function and metabolism regulat-
ing several metabolic responses. The over-activation in stress conditions becomes detrimental for the 
correct functioning of organs leading to the development of metabolic alterations (insulin resistance, 
altered glucose, and lipid metabolism and mitochondrial dysfunction). Among adrenergic receptors, it 
was demonstrated that the activation of βARs subtypes induces insulin resistance75 and, in particular 
the βARs regulates overall glucose homeostasis.14,73 At the cardiac level, β2AR stimulation associated 
with the modulation of fatty acid and glucose metabolism.141 In particular, acute treatment of myocytes 
in vitro or skeletal muscle ex vivo with β2AR agonists increased glucose uptake, comparable to the 
increase produced by insulin stimulation.171 Recent discoveries have suggested that GRK2 is a poten-
tial molecular link between chronic adrenergic stimulation and development of altered myocardial 
metabolism observed during heart failure.74,127 The failing heart is characterized by an upregulation 
of GRK2 levels,2 which is involved in the inhibition of βARs signaling and cardiac inotropism5,172 
(Fig. 11.7).
In addition to the effects on heart function, GRK2 upregulation also affects cardiac metabolism, 
and in particular, myocardial glucose uptake, at the early stages of the disease, when cardiac dila-
tion and reduced function are not yet evident, indicating that metabolic modifications are involved 
in the progression of heart failure. These findings suggest that GRK2 is the molecular link between 
the over-activation of the adrenergic system and the altered glucose uptake during heart failure.5,74 
The connection between GRK2 and insulin signaling derives from the proof of concept that insulin 
increases the cellular content of GRK2.75 Several reports suggest that GRK2 is a crucial modulator 
of insulin resistance, both systemically and in the heart.173 GRK2 can directly induce insulin resist-
ance and reduce glucose metabolism in cardiomyocytes through its catalytic activity. When GRK2 is 
overexpressed in myocytes, there was a decrease in myocardial glucose uptake and impaired insulin 
signaling and fatty acid metabolism.74,174 GRK2 directly phosphorylates IRS1 at the inhibitory Ser307 
residue, inducing the dissociation of the insulin receptor signaling complex and attenuating signaling 
to downstream effectors such as AKT and GLUT4.74,150 Moreover, elevated myocardial GRK2 levels 
exacerbated defects in cardiac glucose metabolism after ischemic injury, before inducing ventricular 
contractile dysfunction,173 demonstrating a proposed link between GRK2 and adrenergic control of 
contractility and metabolism. To further support this concept, myocardial glucose uptake is elevated in 
cardiac-specific GRK2 knockout mice, compared to wild-type mice, and glucose uptake is maintained 
even after ischemia. Moreover, insulin signaling is modified as evidenced by decreased phosphoryla-
tion of IRS1. Overall, glucose metabolism was improved, which prevents heart failure because cardiac 
contractility is not adversely affected.
The interaction between GRK2 and IRS1 is dependent on an intact C terminus of GRK2 as dem-
onstrated in studies using the βARKct peptide, which reproduces the C-terminal sequence, inhibits 
insulin-mediated GRK2-dependent IRS1 phosphorylation, and improves AKT activation and GLUT4 
translocation in response to insulin. Moreover, βARKct gene delivery to the hearts of rats through 
adeno-associated virus serotype 6 before ischemic injury prevented insulin resistance and myocardial 
glucose uptake remained high. These results could suggest that the direct interaction between GRK2 
and IRS1 occurs within the C-terminal tail of GRK2 or that activation of the insulin receptor stimulates 
a pool of G proteins that recruit GRK2 to the membrane through Gβγ where it can interact with IRS1. 
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FIGURE 11.7
GRKs and cardiovascular disease. Persistent sympathetic stimulation of the cardiomyocyte triggers GRK2 
upregulation that aggravates β-AR desensitization and impairs adrenergic signaling. GRK2 upregulation  
due to sympathetic nervous system overdrive has also been shown to be involved in the development of 
insulin resistance. (A) In the nucleus, GRK5 mediates cardiac hypertrophy by phosphorylating hDAC.  
(B) The adrenal gland was recently recognized as an attractive target for hF therapy because adrenal 
medullary chromaffin cells are the sites of catecholamine synthesis. GRK2 upregulation has been correlated 
with elevated catecholamine synthesis and secretion, primarily due to desensitization of the inhibitory α2-AR 
receptors. (C) In the adrenal cortex, angiotensin regulates aldosterone synthesis, where GRK2-β-arrestin 
1–mediated signaling interferes with this regulatory pathway and elevated aldosterone secretion. (D) In the 
kidneys, dopamine 1-R–mediated natriuresis is dampened by GRK4; water and sodium retention are key 
factors of hypertension. (E) In the vasculature, β2-AR–mediated vasodilation is impaired by GRK2, leading 
to hypertension and cardiac and vascular hypertrophy. GRK5 hyperactivity in the vasculature precipitates 
hypertension.
Adapted from Kamal FA, Travers JG, Blaxall BC. G protein–coupled receptor kinases in cardiovascular disease: why “where” matters. 
Trends Cardiovasc Med 2012;22(8):213–19.
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Overall, given the higher efficiency of glucose in ATP production and the lower effect in oxidative 
stress with respect to other substrates, these data argue that the role of GRK2 in the pathogenesis of 
heart failure is due, at least in part, to negative alterations in cardiac metabolism.74,174 Since GRK2 
upregulation causes insulin resistance, its inhibition has positive effects on cellular metabolism. Indeed, 
peptide inhibitors of GRK2 have been designed that prevent its binding to the substrate175 and correct 
glucose levels in diabetic gerbils. In spontaneously hypertensive rats, chronic treatment with a similar 
inhibitor of GRK2 kinase activity, Ant-124, ameliorates the glucose dyshomeostasis and reduction of 
the blood pressure levels.75 Moreover, the inhibition of GRK2 delays the reduction of glucose uptake 
and protects insulin signaling in the heart, preserving cardiac dimension and function.74 This nurtures 
a novel scenario in which GRK2 inhibition might correct impaired metabolism in those conditions 
characterized by poor energy utilization by the cell, such as heart failure. In particular, it is known that 
GRK2 inhibition obtained through means of βARKct transgenic expression of the truncated mutant 
which prevents GRK2 localization on membranes or deletion of GRK2 gene is beneficial for the failing 
heart. Nevertheless, this benefit is thought to be dependent upon inhibition of βARs in the heart.
GRK2 inhibition may lead to an improved cardiac energy utilization. Indeed, as described above, 
during the development of heart failure impaired glucose metabolism precedes depressed cardiac con-
tractility in mice with myocardial infarction.13 These findings support the idea that the inhibition of 
GRK2 kinase activity could be a potential therapeutic target and that excessive elevation of GRK2 
is deleterious for the cell. However, recent evidence challenges this view, since GRK2 exerts differ-
ent effects within the cell depending on its localization, cell type, stimuli, and the pathophysiologi-
cal context (Fig. 11.4). Beside the known localization of GRK2 in plasma membrane and cytosol, 
recently it has been demonstrated that GRK2 is also able to localize in mitochondria under specific 
experimental conditions.51 Such mitochondrial localization suggests a potential role of GRK2 in the 
regulation of energy metabolism but to date there are only few and apparently contradictory reports 
on this topic. In the basal condition, GRK2 is in mitochondria and stressors can induce further accu-
mulation. In macrophages, GRK2 levels in mitochondria increase during inflammation or endotoxin 
stimulation, facilitating biogenesis, and restoring mitochondrial function.176 In the early pathogenesis 
of Alzheimer’s disease and in models of ischemia/reperfusion brain injury, GRK2 accumulates in dam-
aged mitochondria.177 Furthermore, both in hearts in vivo and in cultured myocytes, GRK2 localizes 
into mitochondria after ischemia/reperfusion124. As to the role of GRK2 in mitochondria, in HEK-293 
cells the kinase enhances mitochondrial biogenesis, leading to an increase of ATP cellular content.51 
The removal of GRK2 from the skeletal muscle in vivo leads to reduced ATP production and impaired 
tolerance to ischemia.51 These findings support a positive regulatory role of GRK2 for mitochondrial 
biogenesis and ATP generation.176
In conclusion, GRK2 is involved in the regulation of cell metabolism, and its effects are strictly 
dependent on its subcellular localization. Collectively, the literature demonstrates this kinase is an 
important adaptive mechanism to stress, such as receptor dependent and independent stimuli. As for all 
adaptive mechanisms, the effect is beneficial in the beginning but then becomes detrimental. Indeed, 
increased levels of GRK2 have a deleterious effect in the development of heart failure and insulin resist-
ance when it is increased on plasma membranes,74,75 whereas it is advantageous for energy metabolism 
when it is localized in mitochondria.51,176 Subcellular localization of GRK2 might in the future pose 
the strategy for selective inhibition of the kinase, and the possibility to modulate GRK2 accumulation 
within cellular compartments could be a useful approach to regulate its negative or positive effects on 
cell metabolism.
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PHARMACOLOGY OF ADRENERGIC RECEPTOR BLOCKADE
α-ADRENERGIC RECEPTOR BLOCKADE
As powerful vasodilators, α1AR blockers were initially considered as promising drugs to treat heart 
failure. Nevertheless, chronic administration of the α1AR blocker prazosin led to increased catechola-
mine levels. Two clinical trials failed to support the use of α1AR blockers to treat heart failure: in the 
Veterans Administration Cooperative Study (aka Vasodilator Heart Failure Trial or V-HeFT)) patients 
receiving prazosin experienced worse outcomes than those receiving the combined vasodilator therapy 
of isosorbide dinitrate and hydralazine;178 and in the ALLHAT (Antihypertensive and Lipid-Lowering 
Treatment to prevent Heart Attack Trial) study, the doxazosin arm was terminated early because of 
higher incidence of heart failure.179 Growing evidence indicates that the central nervous system plays 
a determinant role in the sympathetic excitation observed in heart failure.83 Moreover, the association 
between the degree of sympathetic activation and mortality raised the possibility that a more complete 
adrenergic blockade might produce better outcome. Since the excitation of central α2AR inhibits the 
activation of the SNS, such a receptor has been considered a possible target in the treatment of heart 
failure.180 Clonidine is a centrally acting drug with α2AR agonist action that at modest doses can 
markedly attenuates cardiac and renal sympathetic tone in patients with failing hearts enrolled in a 
small and short-term clinical study. However, a trial investigating the centrally acting sympatholytic 
agent moxonidine, had to be terminated early,181 despite a significant dose-related reduction in plasma 
noradrenaline, because the drug was associated with increased mortality and hospitalizations for heart 
failure and myocardial infarction. These findings indicate that peripheral receptor inhibition may be 
better tolerated than central suppression of the SNS. A marked sympatholytic effect has also been asso-
ciated with adverse outcomes in the Beta Blocker Evaluation of Survival Trial, where patients receiving 
bucindolol showed a decrease in noradrenaline levels and exhibited a 169% increase in mortality.182 
Notably, one of the oldest drugs used to treat heart failure, digoxin, which mainly acts by indirectly 
increasing intracellular Ca2+ available in the sarcoplasmic reticulum, has been also shown to modulate 
the adrenergic nervous system by improving baroreceptor function and decreasing sympathetic tone.183
β-ADRENERGIC RECEPTOR BLOCKADE
Based on receptor-level activity, β-blockers can be classified into three generations (Fig. 11.8): (1) first 
generation—nonselective drugs that block both β1AR and β2AR; (2) second generation—cardiose-
lective agents, with higher affinity for β1AR; and (3) third generation—β-blockers with vasodilative 
properties, mediated by α1AR blockade, β2AR agonism, or NO synthesis. Both selective and nonse-
lective β-blockers have negative inotropic and chronotropic effects. The reduced inhibitory effect on 
β2ARs makes the selective β-blockers less likely to cause peripheral vasoconstriction.184 Hence, exer-
cise performance may be impaired to a lesser extent by β1AR selective drugs, at least in part because 
β2AR blockade tends to blunt the exercise-induced increase in skeletal muscle blood flow.103 Exercise 
training can improve βAR signaling and function, augmenting peak oxygen uptake, increasing cardiac 
inotropic reserves, and restoring normal sympathetic outflow and circulating catecholamine levels.103
β-blockers differ in their physicochemical properties. For instance, lipophilic compounds, including 
metoprolol, carvedilol, nebivolol, and bucindolol are rapidly adsorbed in the gastrointestinal tract and 
are extensively metabolized in the liver (first-pass metabolism), resulting in a shorter half-life when 
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FIGURE 11.8
Graphic representation of the molecular structures of the three generations of β-blockers.
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compared to other β-blockers. Additionally, the high lipophilicity leads to an enhanced penetration 
across the blood-brain barrier, which may justify the increased number of central effects as well as the 
membrane-stabilizing properties of antiarrhythmic molecules.185
The most common adverse events of β-blockers are attributable to the blockade of sympathetic 
stimulation, resulting in acute or chronic consequences at cardiovascular, metabolic, and respiratory 
levels.186 In the heart, acute blockade of catecholamine effects worsens myocardial contractility and 
induces bradycardia. Starting with low doses and slowly titrating up is a commonly used approach 
to reduce these risks, patients may experience worsening of their symptoms during β-blocker titra-
tion, often requiring increased diuretic doses. Since a prolonged β-blocker treatment can enhance the 
sensitivity to catecholamines, an abrupt withdrawal should be avoided. As a result of antagonizing 
β2ARs, β-blockers can cause bronchoconstriction, therefore β-blockers, especially nonselective agents, 
are contraindicated in patients suffering from asthma or chronic obstructive pulmonary disease. A risk/
benefit assessment should be performed in each patient to avoid under treatment of heart failure.
The variability in the response to β-blockers has been at least in part ascribed to polymorphisms 
in the cytochrome P450 (CYP) gene CYP2D6, which is highly polymorphic in humans.187 Indeed, 
many β-blockers are partially or totally metabolized by CYP2D6, and opportune dose modifications 
should be accurately considered in patients treated with drugs processed by the same cytochrome 
P450 isoforms, including antipsychotics and antidepressants.188 Equally important, half-life and peak 
plasma concentration are influenced by the formulation of the molecule.189 For instance, metoprolol is 
available in two different formulations: metoprolol-succinate, with a long-lasting action (Metoprolol 
CR/XL Randomized Intervention Trial in Congestive Heart Failure—MERIT-HF), and metoprolol-
tartrate, which has a short half-life and demonstrated a reduced efficacy when compared to carvedilol 
(Carvedilol or Metoprolol European Trial—COMET study). The FDA has approved metoprolol-succi-
nate for the treatment of patients with heart failure.189
Counteracting adrenergic overdrive via βAR antagonists reduces cardiac workload and increases 
O2 sparing in patients with failing heart.
189 However, β-blockers have also noteworthy metabolic impli-
cations, including alterations in the lipoprotein profile, namely, a reduction in high-density lipopro-
tein cholesterol and an increase in triglycerides, and a deranged glucose homeostasis, which can be 
partially attributed to the blockade of β2AR-dependent insulin release from the pancreatic islets of 
Langerhans.14,190 Thus, β1AR selective antagonists are generally preferred in patients with diabetes 
and heart failure.110,186
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